Literature DB >> 8120565

Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.

I Poizot-Martin, M Giovannini, R Rosello, J R Viallat, J F Sauniere, A M Dalmas, D Genre, C Dhiver, J A Gastaut.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8120565     DOI： 10.1200/JCO.1994.12.3.645

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

Review 1.  Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

Authors:  D W Northfelt
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

2.  Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.

Authors:  Yuan-Chin Hsieh; Hsin-Ell Wang; Wen-Wei Lin; Steve R Roffler; Ta-Chun Cheng; Yu-Cheng Su; Jia-Je Li; Chao-Cheng Chen; Chun-Han Huang; Bing-Mae Chen; Jaw-Yuan Wang; Tian-Lu Cheng; Fang-Ming Chen
Journal:  Theranostics       Date:  2018-05-09       Impact factor: 11.556
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.